REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Stack Library

Brain Repair Protocol

Cognitive Enhancementadvanced

80

synergy

80
Share
Peptides

3

Avg Daily mcg

10,850

Level

advanced

Added

May 17, 2026

Overview

The Brain Repair Protocol represents the most aggressive peptide approach to neuroregeneration, combining a potent hepatocyte growth factor (HGF) mimetic with established neuroprotective peptides. Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is a modified angiotensin IV analog that was discovered at Washington State University to be approximately 10 million times more potent than BDNF at promoting neuronal connectivity. It acts as an HGF/c-Met receptor agonist, stimulating the formation of new synaptic connections (synaptogenesis) and promoting the survival of existing neurons. In animal models of cognitive impairment, Dihexa restored learning and memory to levels comparable to young control animals. Semax provides complementary neuroprotection through BDNF/NGF upregulation and modulation of the melanocortin system in the brain. Its effects on neuroplasticity — the brain''s ability to form new neural pathways — make it an ideal companion to Dihexa''s synaptogenic activity. While Dihexa builds new connections, Semax ensures the molecular environment (neurotrophic factors, receptor density) supports the survival and strengthening of those connections through long-term potentiation mechanisms. BPC-157 is included for its documented neuroprotective effects, including modulation of the dopaminergic system, protection against excitotoxic damage (NMDA receptor modulation), and promotion of nerve growth factor expression. In animal models, BPC-157 has shown efficacy against traumatic brain injury, counteracted the effects of neurotoxins, and promoted peripheral nerve regeneration. The three-peptide combination addresses neuroregeneration from multiple angles: structural connectivity (Dihexa), neurotrophic environment (Semax), and neuroprotection/repair (BPC-157). This stack is classified as advanced and researcher-only due to Dihexa''s extreme potency, complete lack of human safety data, and theoretical concerns about its proliferative potential. It is not recommended without medical supervision and thorough risk assessment.

Dosing Protocol

Dihexa

Every day· oral

Read more about Dihexa →

10,000 mcg

per dose

Semax

Every day· nasal

Read more about Semax →

600 mcg

per dose

BPC-157

Every day· subcutaneous

Read more about BPC-157 →

250 mcg

per dose

Goals & Evidence

NeurogenesisMemory repairCognitive declineBrain injuryNeuroprotection
Evidence tier:Animal Studies

Warnings

  • Dihexa is a potent HGF mimetic with NO human trials. Extremely experimental. Semax has Russian approval. BPC-157 is Cat 2. This stack is for researchers only.

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.